Skip to main content

Advertisement

Table 2 Incidence of lesions in Nrf2 mammary tumor study

From: Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene

Lesion WT-% inc KO-% inc p-value
Mammary region    
Hyperplasia 55.9 ± 0.5 46.7 ± 0.5  
Pm (DCIS, early Ca) 67.6 ± 0.5 63.3 ± 0.5  
Mam. carcinoma 58.8 ± 0.5 66.7 ± 0.5  
Sebaceous 2.9 ± 0.2 3.3 ± 0.2  
Adenoacanthoma 5.9 ± 0.2 20.0 ± 0.4 0.091
Lung mets (mc) 5.9 ± 0.2 6.7 ± 0.2  
Sarcoma 8.8 ± 0.3 3.3 ± 0.2  
Other (fibroadenoma, cyst) 8.8 ± 0.3 13.3 ± 0.3  
Lymphomas (by location)    
Lung 23.5 ± 0.4 16.7 ± 0.4  
Spleen 32.4 ± 0.5** 10.0 ± 0.3 0.031
Liver 29.4 ± 0.5 16.7 ± 0.4  
Mediastinal mass 35.3 ± 0.5 20.0 ± 0.4  
Mammary gland 11.8 ± 0.3 6.7 ± 0.2  
Lymph node 0 6.7 ± 0.2  
Other (internal mass, bone) 0 10.0 ± 0.3  
Mice with any lymphoma 47.1 ± 0.5 36.7 ± 0.5  
Any high-grade lymphoma 20.6 ± 0.4** 3.3 ± 0.2 0.042
Other lesions    
Lung adenomas 17.6 ± 0.4** 46.7 ± 0.5 0.012
Skin pap/carc 26.5 ± 0.5 10.0 ± 0.3 0.095
Liver steatosis 23.5 ± 0.4** 3.3 ± 0.2 0.020
Ovarian sex cord stromal 11.8 ± 0.3 6.7 ± 0.2  
  1. Values represent the mean incidence (% Inc.) of lesions ± SD (n = 34 WT, 30 KO). ** Significantly different from KO mice, p ≤ 0.05. Pm, premalignant lesions, mc, mammary carcinoma. P-values are shown for differences that were either significant (p ≤ 0.05) or marginally significant (p ≤ 0.1).